Literature DB >> 19422482

Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice.

Giovanni Latella1, Antonella Vetuschi, Roberta Sferra, Valentina Catitti, Angela D'Angelo, Giuliana Zanninelli, Kathleen C Flanders, Eugenio Gaudio.   

Abstract

BACKGROUND: Hepatic fibrosis is characterized by a progressive accumulation of fibrillar extracellular matrix (ECM) proteins including collagen, which occurs in most types of chronic liver diseases. Transforming growth factor-beta (TGF-beta)/Smad3 signalling plays a central role in tissue fibrogenesis, acting as a potent stimulus of ECM accumulation. AIM: To evaluate the potential protective role of Smad3 deficiency in the pathogenesis of liver fibrosis induced by dimethylnitrosamine (DMN) in Smad3 null mice.
METHODS: Chronic hepatitis-associated fibrosis was induced in 13 Smad3 null and 13 wild-type (WT) mice by intraperitoneal DMN administration (10 microg/g body weight/day) for three consecutive days per week for 6 weeks. The liver was excised for macroscopic examination and histological, morphometric and immunohistochemical (IHC) analyses. For IHC, alpha-smooth muscle actin (alpha-SMA), collagen types I-III, TGF-beta1, connective tissue growth factor (CTGF), Smad3, Smad7 and CD3 antibodies were used.
RESULTS: At macroscopic examination, the liver of DMN-treated Smad3 WT appeared harder with a dark brown colouring and necrotic areas compared with that from null mice. Histological and morphometric evaluation revealed a significantly higher degree of hepatic fibrosis and accumulation of connective tissue in the Smad3 WT compared with null mice. IHC evaluation showed a marked increase in alpha-SMA, CTGF, collagen I-III, TGF-beta and Smad3 staining in the liver of Smad3 WT compared with that in null mice, whereas Smad7 was increased only in null mice.
CONCLUSIONS: The results indicate that Smad3 loss confers resistance to the development of DMN-induced hepatic fibrosis. The reduced fibrotic response appears to be due to a reduction of fibrogenic myofibroblast activation and ECM production and accumulation. Smad3 could be a novel target for potential treatment of fibrosis complicating chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422482     DOI: 10.1111/j.1478-3231.2009.02011.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  41 in total

1.  Analysis of key genes and related transcription factors in liver fibrosis based on bioinformatic technology.

Authors:  Xue Yang; Qi-Ni Cheng; Jiang-Feng Wu; Wen-Bing Ai; Lan Ma
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

Review 2.  Decorin-TGFβ axis in hepatic fibrosis and cirrhosis.

Authors:  Kornélia Baghy; Renato V Iozzo; Ilona Kovalszky
Journal:  J Histochem Cytochem       Date:  2012-01-19       Impact factor: 2.479

3.  Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis.

Authors:  Xiao Ming Meng; Xiao Ru Huang; Arthur C K Chung; Wei Qin; Xinli Shao; Peter Igarashi; Wenjun Ju; Erwin P Bottinger; Hui Yao Lan
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 4.  Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Authors:  Noam Jacob; Stephan R Targan; David Q Shih
Journal:  United European Gastroenterol J       Date:  2016-05-10       Impact factor: 4.623

5.  miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.

Authors:  Jun Xiao; Xiao-Ming Meng; Xiao R Huang; Arthur Ck Chung; Yu-Lin Feng; David Sc Hui; Cheuk-Man Yu; Joseph Jy Sung; Hui Y Lan
Journal:  Mol Ther       Date:  2012-03-06       Impact factor: 11.454

Review 6.  Animal models for the study of liver fibrosis: new insights from knockout mouse models.

Authors:  Hiromitsu Hayashi; Takao Sakai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

Review 7.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

8.  Dysregulation of upstream and downstream transforming growth factor-β transcripts in livers of children with biliary atresia and fibrogenic gene signatures.

Authors:  Tatiana Iordanskaia; Monica J Hubal; Emily Koeck; Christopher Rossi; Kathleen Schwarz; Evan P Nadler
Journal:  J Pediatr Surg       Date:  2013-10       Impact factor: 2.545

Review 9.  TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis.

Authors:  Fengyun Xu; Changwei Liu; Dandan Zhou; Lei Zhang
Journal:  J Histochem Cytochem       Date:  2016-01-08       Impact factor: 2.479

Review 10.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.